Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 04, 2015 11:28 PM ET

Pharmaceuticals

Company Overview of Boston Therapeutics, Inc.

Company Overview

Boston Therapeutics, Inc. focuses on the development, manufacture, and commercialization of therapeutic drugs based on complex carbohydrate chemistry to address unmet medical needs in diabetes and inflammatory diseases. It offers SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. The company’s product pipeline includes BTI-320, a non-systemic chewable therapeutic compound, which has completed a Phase II clinical trial to reduce post-meal glucose elevation; IPOXYN, an injectable anti-necrosis drug candidate for the treatment of lower limb ischemia associated with diabetes; and OxyFex for use as an oxygen delivery agent in ve...

1750 Elm Street

Suite 103

Manchester, NH 03104

United States

Founded in 2009

7 Employees

Phone:

603-935-9799

Fax:

603-685-4784

Key Executives for Boston Therapeutics, Inc.

Founder, Chairman, Chief Executive Officer and Treasurer
Age: 60
Total Annual Compensation: $100.0K
Chief Financial Officer, Principal Accounting Officer and Vice President of Strategic Planning & Investor Relations
Age: 71
Total Annual Compensation: $98.4K
Compensation as of Fiscal Year 2014.

Boston Therapeutics, Inc. Key Developments

Boston Therapeutics, Inc. Presents at 2nd Annual Growth Capital Expo, Apr-13-2015

Boston Therapeutics, Inc. Presents at 2nd Annual Growth Capital Expo, Apr-13-2015 . Venue: Caesars Palace, Las Vegas, Nevada, United States.

Boston Therapeutics, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Fiscal Year Ended December 31, 2014

Boston Therapeutics, Inc. reported unaudited earnings results for the fourth quarter and fiscal year ended December 31, 2014. For the quarter, the company reported revenue of $12,871 compared to revenue of $80,438 for the fourth quarter ended December 31, 2013. Net loss was $762,495 or $0.02 per basic and diluted share, compared with a net loss of $2,297,972 or $0.06 per basic and diluted share in the prior year's fourth quarter. Operating loss was $756,854 compared to $2,293,123 a year ago. For the year, the company reported revenue of $199,582 compared to revenue of $323,412 for fiscal 2013. The decrease for fiscal 2014 is primarily due to decreased shipments of SUGARDOWN to the company's one significant customer, APC. Net loss was $4,699,939 or $0.12 per basic and diluted share, compared with a net loss of $4,601,503 or $0.18 per basic and diluted share for fiscal 2014. Operating loss was $4,674,347 compared to $4,580,245 a year ago.

Boston Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Boston Therapeutics, Inc. filed its 10-K on Mar 27, 2015 for the period ending Dec 31, 2014. In this report its auditor, McGladrey LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Similar Private Companies By Industry

Company Name Region
Novartis Animal Health US, Inc. United States
Angels' Eyes United States
STWB Inc. United States
Merck Sharp & Dohme Quimica de Puerto Rico, Inc. United States
Mt. Cook Pharma, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
March 18, 2015
--
Private Placement
March 13, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Boston Therapeutics, Inc., please visit www.bostonti.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.